LEADER 03085nam  2200565 a 450 
001 9910816724603321
005 20240410171037.0
010   $a1-61470-207-1
035   $a(CKB)2670000000149002
035   $a(EBL)3019817
035   $a(SSID)ssj0000691226
035   $a(PQKBManifestationID)12225615
035   $a(PQKBTitleCode)TC0000691226
035   $a(PQKBWorkID)10629372
035   $a(PQKB)11478296
035   $a(MiAaPQ)EBC3019817
035   $a(Au-PeEL)EBL3019817
035   $a(CaPaEBR)ebr10671382
035   $a(OCoLC)777549337
035   $a(EXLCZ)992670000000149002
100   $a20090625d2009      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aMannose-binding lectin in the innate immune system$b[electronic resource] /$fIara de Messias-Reason and Angelica B.W. Boldt
205   $a1st ed.
210   $aHauppauge, N.Y. $cNova Biomedical Books$d2009
215   $a1 online resource (99 p.)
300   $aDescription based upon print version of record.
311   $a1-60692-716-7 
320   $aIncludes bibliographical references and index.
327   $aIntro -- MANNOSE-BINDING LECTIN INTHE INNATE IMMUNE SYSTEM -- MANNOSE-BINDING LECTIN INTHE INNATE IMMUNE SYSTEM -- CONTENTS -- PREFACE -- INTRODUCTION -- 1. MANNOSE BINDING LECTIN (MBL)CHARACTERISTICS -- 1a. MBL2 Gene and Protein Structure -- 1b. MBL2 Transcription and Translation -- 2. MBL FUNCTIONS -- 2a. Activation of Complement -- 2b. Opsonophagocytosis -- 2c. Modulation of Inflamation -- 2d. Recognition of Altered Self and Apoptosis -- 2e. Other MBL Functions -- 3. MBL2 GENE POLYMORPHISM -- 3a. MBL2 Variants and Allelic Haplotypes -- 3b. Worldwide Distribution of MBL2 Haplotypes -- MBL2 ASSOCIATION WITH DISEASES -- 1. POSITIVE ASSOCIATION OF MBL DEFICIENCYWITH DISEASES -- 1a. Otitis Media and other Pediatric Infections -- 1b. Meningitis -- 1c. Mycoplasma Infection -- 1d. Emergent Viral Infection -- 1e. Fungal Infections -- 1f. Malaria -- 1g. Neutropenia -- 1h. Hepatitis B -- 1i. HIV Infection -- 1j. Cystic Fibrosis -- 1k. Systemic Inflammatory Response Syndrome -- 1l. Cardiovascular Diseases -- 1m. Systemic Lupus Erythematosus -- 1n. Gastrointestinal Diseases -- 2. NEGATIVE ASSOCIATION OF MBL DEFICIENCYWITH DISEASES -- 2a. Leprosy -- 2b. Tuberculosis -- 2c. Leishmaniasis -- 2d. Hepatitis C -- 2e. Rheumatic Heart Disease -- 2f. Rheumatoid Arthritis -- 2g. Ischemia/Reperfusion Injury -- 2h. Other Diseases -- 3. MBL AND HETEROZYGOTE ADVANTAGE -- 4. MBL THERAPY -- CONCLUSION -- REFERENCES -- INDEX.
606   $aLectins
606   $aNatural immunity
606   $aMannose
615  0$aLectins.
615  0$aNatural immunity.
615  0$aMannose.
676   $a616.079
700   $aDe Messias-Reason$b Iara$01695838
701   $aBoldt$b Angelica B. W$01695839
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910816724603321
996   $aMannose-binding lectin in the innate immune system$94075370
997   $aUNINA